The Hematology/Oncology Pharmacy Association has helped establish practical guidance for Investigational Services metrics and site utilization.

The metrics subgroup of the HOPA Investigational drug services (IDS) special interest group recently conducted a survey-based project to help establish practical guidance for IDS metrics and site utlity. Three surveys were sent to HOPA IDS professionals to document how metrics were currently gathered at various sites, categorize and define additional approaches, and create a list of recommended metrics for every IDS site to track. The recommended metrics can serve as a basis for standardization and benchmarking for sites mired in the complexity of research protocols.

The results have been published in the American Journal of Health-Systems Pharmacy.


Authors: Molly Schmidt, PharmD, BCPS, BCOP, CSP; Lisa Janssen Carlson, PharmD, BCOP; Jennifer Murphy, PharmD, BCOP, Sapna R Amin, PharmD, BCOP; Robin Lockhorst, PharmD, BCOP, BCPS; and Kyle Luedtke, PharmD

Read the abstract

An image of acute lymphoblastic leukemia cells
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Obecabtagene autoleucel

Crystal Chung, PharmD, PGY2 Oncology Pharmacy Resident, and Emma Sheldon, PharmD, BCOP, Oncology Pharmacy Specialist - Bone Marrow Transplant/Cellular Therapy, both from Scripps Health in San Diego, CA, discuss obecabtagene autoleucel (Aucatzyl).

An image of a brain x-ray
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Dordaviprone

Nghi Nguyen, PharmD, PGY1 Pharmacy Resident, and Andrea Clarke, PharmD, BCOP, Hematology/Cellular Therapy Clinical Pharmacy Specialist - both from Wellstar MCG Health in Augusta, GA - deep dive into the potential role and clinical pearls of dordaviprone.

An image of multiple myeloma cells
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Linvoseltamab-gcpt

Nikki Kalem, PharmD, PGY2 Oncology Pharmacy Resident, at Henry Ford Hospital in Detroit, MI, writes about the recent accelerated approval of linvoseltamab-gcpt for the treatment of relapsed or refractory multiple myeloma in adults.